Immunotherapeutic targeting of Wilms' tumor protein.
The expression of Wilms' tumor protein (WT1)-derived peptides on malignant cell surfaces and recognition of those peptides by cellular and humoral immune responses suggest that WT1 may be a promising potential target antigen in immunotherapeutic trials. With a high frequency of expression in hematopoietic as well as solid tumors, WT1 is a broadly applicable target. Both in vivo mouse model and in vitro human studies have demonstrated the ability of WT1-specific cytotoxic T-lymphocytes to lyse WT1-expressing malignancies without harming normal tissue. WT1-peptide vaccination, in combination with adjuvants, has demonstrated the ability to activate WT1-specific immune responses and evidence of clinical activity. Because peptide-based vaccines are human leukocyte antigen-restricted, other more broadly applicable strategies are now being developed to activate WT1-specific immune responses, including the use of WT1-specific viral vectors.
Hutchings
Yalonda
Y
Duke University Medical Center, Departments of Medicine and Surgery, 401 MSRB, Research Drive, Durham, NC 27710, USA.
Osada
Takuya
T
Woo
Christopher Y
CY
Clay
Timothy M
TM
Lyerly
H Kim
HK
Morse
Michael A
MA
D000818:Animals; D002986:Clinical Trials as Topic; D015395:Histocompatibility Antigens Class I / Q000276:immunology; D000949:Histocompatibility Antigens Class II / Q000276:immunology; D006801:Humans; D007167:Immunotherapy; D025721:WT1 Proteins / Q000235:genetics / Q000378:metabolism*; D009396:Wilms Tumor / Q000235:genetics / Q000276:immunology* / Q000628:therapy*
D015395:Histocompatibility Antigens Class I; D000949:Histocompatibility Antigens Class II; D025721:WT1 Proteins